Artificial oxygen carriers based on perfluorodecalin-filled poly(n-butyl-cyanoacrylate) nanocapsules

References

• Al Khouri Fallouh N. 1984a. Nanocapsules ou nanoparticules biodégradables contenant une substance biologiquement active, leur préparation et leur application. French Patent No 8120801
   Google Scholar
• Al Khouri Fallouh N. 1984b. Nanocapsules de polyalkylcyanoacrylates. Nouveaux vecteurs de médicaments, Etude galénique et pharmacocinétique. PhD thesis, Paris, France
   Google Scholar
• Al Khouri Fallouh N, Roblot-Treupel L, Fessi H, Devissaguet JPh, Puisieux F. Development of a new process of the manufacture of polyisobutylcyanoacrylate nanocapsules. Int J Pharmaceutics, 1986;28:125–32
   Google Scholar
• Bauer J, Zähres M, Zellermann A, Kirsch M, Petrat F, de Groot H, Mayer C. Perfluorocarbon-filled poly(lactide-co-glycolide) nano- and microcapsules as artificial oxygen carriers for blood substitutes: A physico-chemical assessment. J Microencapsulation, 2010;27:122–32
   PubMed Web of Science ®Google Scholar
• Chang TMS. Semipermeable microcapsules. Science, 1964;146:524–5
   PubMed Web of Science ®Google Scholar
• Chang TMS. Future generations of red blood cell substitutes. J Intern Med, 2003;253:527–35
   PubMed Web of Science ®Google Scholar
• Chang TMS. Artificial cells for cell and organ replacements. Artificial Organs, 2004;28:265–70
   PubMed Web of Science ®Google Scholar
• Chaudhari KR, Ukawala M, Manjappa AS, Kumar A, Mundada PK, Mishra AK, Mathur R, Mönkkönen J, Murthy RSR. Opsonization, biodistribution, cellular uptake and apoptosis study of PEGylated PBCA nanoparticle as potential drug delivery carrier. Pharm Res, 2012;29:53–68
   PubMed Web of Science ®Google Scholar
• Clark LC, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science, 1966;152:1755–6
   PubMed Web of Science ®Google Scholar
• Couvreur P, Vauthier C. Polycyanoacrylate nanoparticles as drug carrier: Present state and perspectives. J Controlled Release, 1991;17:187–98
   Web of Science ®Google Scholar
• Douglas SJ, Davis SS, Illum L. Biodistribution of poly(butyl 2-cyanoacrylate) nanoparticles in rabbits. Int J Pharm, 1986;34:145–52
   Web of Science ®Google Scholar
• European Community. Official Journal of the European Union 2010;L276:33–79
   Google Scholar
• Faithfull NS, King CE, Cain SM. Peripheral vascular responses to fluorocarbon administration. Microvasc Res, 1987;33:183–93
   PubMedGoogle Scholar
• Ferenz KB, Waack IN, Mayer C, de Groot H, Kirsch M. Long-circulating poly(ethylene glycol)-coated poly(lactid-co-glycolid) microcapsules as potential carriers for intravenously administered drugs. J Microencapsulation, in press. doi:10.3109/02652048.2013.770098
   Google Scholar
• Gallardo M, Couarraze G, Denizot B, Treupel L, Couvreur P, Puisieux F. Study of the mechanisms of formation of nanoparticles and nanocapsules of polyisobutyl-2-cyanoacrylate. Int J Pharm, 1993;100:55–64
   Web of Science ®Google Scholar
• Ganachaud F, Katz JL. Nanoparticles and nanocapsules crated using the ouzo effect: Spontaneous emulsification as an alternative to ultrasonic and high-shear devices. ChemPhysChem, 2005;6:209–16
   PubMed Web of Science ®Google Scholar
• Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influence of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces, 2000;18:301–13
   PubMed Web of Science ®Google Scholar
• Grislain L, Couvreur P, Lenearts V, Roland M, Deprez-Decampeneere D, Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm, 1983;15:335–45
   Web of Science ®Google Scholar
• Gustafsson MGL. Surpassing the lateral resolution limit by a factor of two using structured illumination microscopy. J Microsc, 2000;198:82–7
   PubMed Web of Science ®Google Scholar
• Illum L, Davis SS. The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (Poloxamer 338). FEBS Lett, 1984;167:79–82
   PubMed Web of Science ®Google Scholar
• Ingram DA, Forman MB, Murray JJ. Activation of complement by Fluosol attributable to the pluronic detergent micelle structure. J Cardiovasc Pharmacol, 1993;22:456–61
   PubMed Web of Science ®Google Scholar
• Kirsch M, Bramey T, Waack IN, Petrat P, Mayer C, de Groot H. The necessity for the coating of perfluorodecalin-filled poly(lactide-co-glycolide) microcapsules in the presence of physiological cholate concentrations: Tetronic-908 as exemplary polymeric surfactant. J Microencapsulation, 2012;29:30–8
   PubMed Web of Science ®Google Scholar
• Kost J, Leong K, Langer R. Ultrasound-enhanced polymer degradation and release of incorporated substances. Proc Natl Acad Sci USA, 1989;86:7663–6
   PubMed Web of Science ®Google Scholar
• Lenaerts V, Couvreur P, Christiaens-Leyh D, Joiris E, Roland M. Degradation of poly(isobutylcyanoacrylate) nanoparticles. Biomaterials, 1984;5:65–8
   PubMed Web of Science ®Google Scholar
• Lowe KC. Engineering blood: Synthetic substitutes from flourinated compounds. Tissue Eng, 2003;9:389–99
   PubMedGoogle Scholar
• Mattrey RF, Hilpert PL, Long CD, Long DM, Mitten RM, Peterson T. Hemodynamic effects of intravenous lecithin-based perfluorocarbon emulsions in dog. Crit Care Med, 1989;17:652–6
   PubMed Web of Science ®Google Scholar
• Nicolas J, Couvreur P. Synthesis of poly(alkylcyanoacrylate)-based colloidal nanomedicines. Rev Nanomed Nanobiotechnol, 2009;1:111–27
   PubMed Web of Science ®Google Scholar
• Pisani E, Tsapis N, Paris J, Nicolas V, Cattel L, Fattal E. Polymeric nano/microcapsules of liquid perfluorocarbons for ultrasonic imaging: Physical characterization. Langmuir, 2006;22:4397–402
   PubMed Web of Science ®Google Scholar
• Riess JG. Reassessment of criteria for the selection of perfluorochemicals for 2nd generation blood substitutes – Analysis of structure property relationships. Artif Organs, 1984;8:44–56
   PubMed Web of Science ®Google Scholar
• Riess JG. Oxygen carriers («blood substitutes») – Raison d’être, chemistry, and some physiology. Chem Rev, 2001;101:2797–919
   PubMed Web of Science ®Google Scholar
• Sloviter HA, Kamimoto T. Erythrocyte substitute for perfusion of brain. Nature, 1967;216:458–60
   PubMed Web of Science ®Google Scholar
• Tremper KK, Friedmann AE, Levine EM, Lapin R, Camarillo D. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA. N Engl J Med, 1982;307:277–83
   PubMed Web of Science ®Google Scholar
• Vercellotti GM, Hammerschmidt DE, Craddock PR. Activation of plasma complement by perfluorocarbon artificial blood: Probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis. Blood, 1982;59:1299–304
   PubMed Web of Science ®Google Scholar
• Vitale SA, Katz JL. Liquid droplet dispersions formed by homogeneous liquid-liquid nucleation: “The ouzo effect”. Langmuir, 2003;19:4105–10
   Web of Science ®Google Scholar
• Waxman K, Cheung CK, Mason GR. Hypotensive reaction after infusion of a perfluorochemical emulsion. Crit Care Med, 1984;12:609–10
   PubMedGoogle Scholar
• Winslow RM. Current status of oxygen carriers (“blood substitutes”) 2006;91:102–10
   Google Scholar